Formulation: A solid
Formal Name: 6α,9-difluoro-11β-hydroxy-16α-methyl-3-oxo-17α-[[(2,2,3,3-tetramethylcyclopropyl)carbonyl]oxy]-androsta-1,4-diene-17-carboxylic acid, cyanomethyl ester
Purity: ≥98%
Formula Markup: C31H39F2NO6
Formula Weight: 559,6
Shelf life (days): 1460
CAS Number: 827319-43-7
Notes: GW 870086 is a cyano- and isopropyl-substituted derivative of the synthetic corticosteroid and glucocorticoid receptor agonist fluticasone propionate (Item No. 20703).{66794} It selectively inhibits TNF-α-induced transcriptional activity of NF-κB in a reporter assay using A549 cells (IC50 = 0.08 nM) over a panel of 50 steroid receptors in reporter assays using CV-1 cells at 1 µM. GW 870086 (5 nM) prevents TNF-α-induced increases in the expression of mRNA encoding COX-2 and TNF-C, also known as lymphotoxin-β (LT-β), in A549 lung cancer cells. It inhibits TNF-α-induced increases in IL-8 secretion in 16HBE bronchial epithelial cells in a concentration-dependent manner. In vivo, GW 870086 (30 µg/animal) reduces oxazolone-induced increases in ear swelling in a mouse model of contact dermatitis, as well as inhibits ovalbumin-induced bronchoconstriction and increases in the number of eosinophils in the bronchoalveolar lavage fluid (BALF) in mice when administered at doses of 30 or 100 µg/animal per day.